Company: ABUS
Filing Date: 2025-04-04
Form Type: DEF 14A
Source: 0001140361-25-012305
Chunk: 1

Company: Arbutus Biopharma Corp
Filing Date: 2025-04-04
Form: DEF 14A
Chunk 1
---
 |
| Lindsay Androski, JD, MBA, CFA        |
| Chairperson of the Board of Directors |

TABLE OF CONTENTS

ARBUTUS BIOPHARMA CORPORATION 701 Veterans Circle Warminster, Pennsylvania 18974, United States (267) 469-0914 NOTICE OF 2025 ANNUAL GENERAL MEETING OF SHAREHOLDERS TO BE HELD WEDNESDAY, MAY 21, 2025 Dear Shareholders of Arbutus Biopharma Corporation: NOTICE IS HEREBY GIVEN that the 2025 Annual General Meeting of Shareholders (the “Annual Meeting”) of Arbutus Biopharma Corporation, a British Columbia corporation (“Arbutus”, the “Company”, “we”, “us”, and “our”), will be held on Wednesday, May 21, 2025 at 10:00 a.m. (Eastern Daylight Time) solely by means of live audio webcast online at www.virtualshareholdermeeting.com/ABUS2025, for the following purposes:

| 1. | ELECTION OF DIRECTORS. To elect the five (5) director nominees of Arbutus named in the accompanying Management Proxy Circular and Proxy Statement each to serve until the 2026 Annual General Meeting of Shareholders or until his or her qualified successor has been duly elected or appointed; |

| 2. | ADVISORY VOTE TO APPROVE THE COMPENSATION OF OUR NAMED EXECUTIVE OFFICERS. To approve, on a non-binding advisory basis, the compensation of our named executive officers as disclosed in the accompanying Management Proxy Circular and Proxy Statement (commonly referred to as a “Say on Pay” vote); |

| 4. | ANY OTHER BUSINESS. To transact such other business as may properly come before the Annual Meeting, or at any adjournments or postponements thereof. |

The foregoing matters are more fully described in the accompanying Management Proxy Circular and Proxy Statement. We recommend that our shareholders vote “ FOR ALL” for Proposal No. 1 and “ FOR” Proposal Nos. 2 and 3. Although not part of the Management Proxy Circular and Proxy Statement accompanying this Notice, we are also making available our 2024 Annual Report on Form 10-K for the year ended December 31, 2024 (the “Annual Report”), which includes our audited annual financial statements prepared in accordance with United States generally accepted accounting principles for the fiscal year ended December 31, 2024 (the “Annual Financial